Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s share price traded down 4.5% on Monday . The stock traded as low as $13.78 and last traded at $13.67. 448,285 shares changed hands during mid-day trading, a decline of 12% from the average session volume of 510,065 shares. The stock had previously closed at $14.32.

Analyst Ratings Changes

A number of equities analysts have issued reports on MLYS shares. Jefferies Financial Group began coverage on Mineralys Therapeutics in a report on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price objective on the stock. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Guggenheim set a $48.00 price objective on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $42.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, Mineralys Therapeutics has a consensus rating of "Hold" and a consensus price target of $32.25.

Mineralys Therapeutics Trading Down 6.1%

The business has a fifty day simple moving average of $14.74 and a two-hundred day simple moving average of $12.84. The company has a market cap of $876.60 million, a PE ratio of -3.70 and a beta of -0.17.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.23. Equities analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Activity at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 55,771 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the transaction, the insider now directly owns 116,704 shares of the company's stock, valued at $1,839,255.04. This trade represents a 32.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.06, for a total transaction of $129,729.42. Following the completion of the sale, the chief financial officer now directly owns 215,340 shares of the company's stock, valued at $2,597,000.40. The trade was a 4.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,579 shares of company stock worth $1,534,353 in the last three months. 25.56% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Mineralys Therapeutics by 2.7% during the fourth quarter. Bank of New York Mellon Corp now owns 65,318 shares of the company's stock worth $804,000 after acquiring an additional 1,711 shares during the period. Proficio Capital Partners LLC purchased a new stake in Mineralys Therapeutics in the 4th quarter worth approximately $285,000. Charles Schwab Investment Management Inc. increased its stake in Mineralys Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 214,906 shares of the company's stock valued at $2,645,000 after purchasing an additional 1,307 shares during the last quarter. Candriam S.C.A. purchased a new position in shares of Mineralys Therapeutics during the 4th quarter worth about $3,758,000. Finally, AlphaQuest LLC grew its stake in shares of Mineralys Therapeutics by 2,637.8% during the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company's stock valued at $187,000 after buying an additional 14,666 shares during the period. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.